{"schema_version":"secwatch.filing_event.v1","accession":"0001625297-25-000025","form_type":"8-K","ticker":"INDV","cik":"0001625297","company_name":"Indivior Pharmaceuticals, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.229273+00:00","generated_at":"2026-05-24T03:56:01.837795+00:00","sec_items":["7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.75,"confidence":"high","headline":"Indivisor names Joe Ciaffoni CEO; proposes incentive plan with share price targets up to $35","bullets":["Joe Ciaffoni to become CEO effective upon shareholder approval of new Directors' Remuneration Policy at May 8, 2025 AGM.","On-hire PSU award up to 1.575M shares vests based on VWAP targets: $15, $20, $25, $30, $35 over 1–5 years.","On-hire RSU award of 525,000 shares with cliff vest on 3rd anniversary of start date.","Proposed policy increases LTIP on-target grant to 400% of salary in 2026 and 700% in 2027.","Benchmarked vs US biopharma peers; CEO's potential dilution <2% of value created for shareholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001625297-25-000025","json":"https://secwatch.observer/filing/0001625297-25-000025.json","markdown":"https://secwatch.observer/filing/0001625297-25-000025.md","text":"https://secwatch.observer/filing/0001625297-25-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000025/0001625297-25-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625297/000162529725000025/indv-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:56:01.837795+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}